Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab + PD-1 Inhibitor in Stage III/IV Melanoma
NCT03620019Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2018
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in melanoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Change in Recent Thymic Emigrant Cells in Peripheral Blood at 3 weeks, Change in Density of Tumor-infiltrating CD8+ Cells in Tumor Tissue at 3 weeks and 1 more. Started Sep 2018; status: completed.
02
Drugs
denosumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03620019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620019.